Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years.
FLT3 mutations
acute myeloid leukemia (AML)
chemotherapy
complete remission (CR)
hematopoietic stem cell transplantation (HSCT)
long-term outcomes
midostaurin
minimal residual disease (MRD)
relapse
tyrosine kinase inhibitors (TKIs)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Aug 2024
17 Aug 2024
Historique:
received:
28
06
2024
revised:
10
08
2024
accepted:
15
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
We analyzed 140 patients with a median age of 51 years; 21% had WBC ≥ 100 × 10
Identifiants
pubmed: 39199635
pii: cancers16162864
doi: 10.3390/cancers16162864
pii:
doi:
Types de publication
Journal Article
Langues
eng